Medarex in two deals

Eos (South San Francisco, Calif.) will identify targets for cancer and other diseases, and will use MEDX's HuMAb-Mouse technology to develop human antibodies against the targets. Eos is responsible for developing the antibodies through Phase IIa testing, and the companies will jointly own six to nine of these products. MEDX will have an option to receive exclusive marketing rights in Europe to certain antibodies. Eos will receive a $5 million upfront payment and up to $20 million in clinical milestones. MEDX also will provide Eos with credits against future milestones and royalties that would otherwise be payable in connection with Eos' use of MEDX's HuMAb-Mouse technology over several years.

Separately, MEDX and Immuno-Designed Molecules (Paris, France) expanded a 1993 partnership under which Immuno-Designed will receive additional MEDX technologies for developing bispecific and monoclonal antibodies, including HuMAb-Mouse, to treat prostate, colorectal, bladder and breast cancer. MEDX, which owns 6 percent of Immuno-Designed, may increase its ownership to 43 percent of the company or equivalent ownership in a joint venture between the companies. Immuno-Designed will receive $2 million and could receive an additional $5 million in exchange for the ownership rights. MEDX will receive up to $2 million in research funding over two years. ...